Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 11, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Hypertension,Essential
Interventions
DRUG

SPH3127 tablet Dose 1

Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.

DRUG

SPH3127 tablet Dose 2

Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.

DRUG

SPH3127 tablet Dose 3

Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.

DRUG

SPH3127 tablet Placebo

Oral SPH3127 tablet placebo, once daily for 8 weeks.

Trial Locations (10)

Unknown

Beijing Anzhen Hospital, Capital Medical University, Beijing

Beijing Hospital, Beijing

The Second Xiangya Hospital of Central South University, Changsha

Xiangya Hospital Central South University, Changsha

West China Hospital of Sichuan University, Chengdu

Second People's Hospital of Guangdong Province, Guangdong

Inner Mongolia Medical University Affiliated Hospital, Hohhot

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Xuzhou Central Hospital, Xuzhou

All Listed Sponsors
collaborator

R&G Pharma Studies Co.,Ltd.

INDUSTRY

lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT03756103 - Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients | Biotech Hunter | Biotech Hunter